Population
10 patients (9 male, age 11-18 years) with BCOR-CCNB3 sarcoma
Design
Cohort
Follow-up
up to 10 years
Authors
Loading...
Survival comparable to Ewing sarcoma may support similar management; leaves open whether distinct biology warrants tailored therapy.
BCOR-CCNB3 sarcomas have distinct histologic and immunohistochemical features from typical Ewing sarcoma, though overall survival is not statistically different.
Puls et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: